Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Shares Outstanding (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Shares Outstanding data on record, last reported at $215.9 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 36.88% year-over-year to $215.9 million; the TTM value through Dec 2025 reached $215.9 million, up 36.88%, while the annual FY2025 figure was $215.9 million, 36.88% up from the prior year.
  • Shares Outstanding reached $215.9 million in Q4 2025 per OCUL's latest filing, up from $174.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $215.9 million in Q4 2025 and bottomed at $76.2 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $115.6 million, with a median of $79.3 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: rose 0.53% in 2022, then skyrocketed 99.58% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $76.7 million in 2021, then increased by 0.61% to $77.2 million in 2022, then skyrocketed by 48.91% to $115.0 million in 2023, then skyrocketed by 37.22% to $157.7 million in 2024, then surged by 36.88% to $215.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $215.9 million in Q4 2025, $174.9 million in Q3 2025, and $172.9 million in Q2 2025.